|
|
|
|
|
|
|
|
|
|
abstract
"Cancer-related pain is a common clinical
problem, experienced by ∼90% of patients with cancer. The mainstay of
treatment remains
opioids and the WHO analgesic ladder. Following the
principles of the analgesic ladder, 80% of patients can achieve pain
control.
However, breakthrough pain remains a form of
cancer-related pain that is particularly difficult to manage in both
specialist
and generalist settings. The focus of this article
is the mismatch between the temporal characteristics of the majority of
cancer-related breakthrough pain which is fast
onset and resolution, with the pharmacological profile of oral morphine.
The
contribution of fast-acting fentanyl preparations
to the treatment of breakthrough pain and the evidence for the various
commercially
available preparations will be considered."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.